<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02153437</url>
  </required_header>
  <id_info>
    <org_study_id>CV205-006</org_study_id>
    <nct_id>NCT02153437</nct_id>
  </id_info>
  <brief_title>Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers</brief_title>
  <official_title>A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of our compound (BMS-919373) on electrical activity of the heart
      using pacemakers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of BMS-919373 on Atrial effective refractory period (AERP) in subjects with a dual chamber pacemaker</measure>
    <time_frame>At 0.5, 1, 2, and 4 hours following study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety assessments will be based on Adverse event reports, vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests</measure>
    <time_frame>At 1, 2, and 4 hours following study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments based on Ventricular Effective Refractory Period (VERP) and change from baseline</measure>
    <time_frame>At 2 hour following study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments based on Atrioventricular interval (AVI) and change from baseline</measure>
    <time_frame>At 1, 2, and 4 hours following study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments based on Wenckebach cycle length (WCL) and change from baseline</measure>
    <time_frame>At 1, 2, and 4 hours following study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments based on Intra-atrial conduction time (IACT) and change from baseline</measure>
    <time_frame>At 1, 2, and 4 hours following study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Arm A: BMS-919373</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-919373 oral Solution/tablet single dose for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Sotalol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sotalol oral Tablet single dose for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Placebo for BMS-919373</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral solution/tablet one single dose for one day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-919373</intervention_name>
    <arm_group_label>Arm A: BMS-919373</arm_group_label>
    <other_name>iKUR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotalol</intervention_name>
    <arm_group_label>Arm B: Sotalol</arm_group_label>
    <other_name>Co Sotalol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for BMS-919373</intervention_name>
    <arm_group_label>Arm C: Placebo for BMS-919373</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Age 18 years to 85 years

          -  Eligible patients will have a dual-chamber permanent pacemaker

          -  Women who are not of childbearing potential

        Exclusion Criteria:

          -  Patients with a history of Atrial Fibrillation (AF) that is either

               -  (i) Permanent (i.e. patients are only in AF and never in sinus rhythm) or

               -  (ii) Persistent (i.e. patients who's episodes of AF are longer than 7 days and
                  require medical intervention, such as electrical or medical cardioversion, to
                  return to sinus rhythm), are excluded

          -  History of Transient Ischemic Attack (TIA) or stroke in the last 12 months

          -  History of clinically significant ventricular arrhythmia (not including isolated
             monomorphic Premature Ventricular Contractions (PVCs)). Such arrhythmias are marked by
             loss of consciousness, emergent cardioversion or defibrillation or unstable vital
             signs requiring medical intervention

          -  Complete heart block

          -  Planned surgery, endovascular intervention or cardioversion within the study period

          -  History of atrial fibrillation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael'S Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sotalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

